Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $465M. The Maz Rating grades it against the other companies in its sector.
Aquestive Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.70, Aquestive Therapeutics, Inc. trades at 9.5x sales. Over the last twelve months it generated about $49M of revenue and a net loss of $81M. It runs a gross margin of 65.3%, an operating margin of -114.1% and a net margin of -162.3%. It shows return on equity of 255.1%, return on invested capital of -54.3% and a free cash flow yield of -8.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.12. Over the past 52 weeks the share price ranged from $2.93 to $6.74, with a beta of 1.50.
Aquestive Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Aquestive Therapeutics, Inc. (AQST) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.01% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.2% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.01% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.2% / 33% · Receivables / Mkt Cap (36m) 0.94% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.01% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.2% / 33.33% · Receivables / Mkt Cap (24m) 0.94% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 55.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 76.1% / 33.33% · Receivables / Avg Assets (4Q) 7.09% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.03% / 33.33% · (Cash+ST Inv) / Total Assets 75.7% / 33.33% · (Cash+Recv) / Total Assets 80.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Aquestive Therapeutics, Inc. (AQST) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Aquestive Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Aquestive Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.